Definitive Contract 75F40121C00109
Award Date 8/27/21
Potential Completion Date 3/14/26
Potential Value $2.8M
Federal Agency
Ultimate Awardee
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a Firm Fixed Price definitive contract awarded by the Department of Health and Human Services Food and Drug Administration to the University of California, Los Angeles (UCLA) under the Broad Agency Announcement FDAVAA-19-00123-A3 "Strengthening the Global Product Safety Net, Research Area #9". The contract has a potential value of $723,268.00 and a performance completion date of March 14, 2022. The contract is not set aside for any small business designation. UCLA is performing...
- This is a Cost No Fee definitive contract awarded by the Food and Drug Administration (FDA) to the University of California, Los Angeles (UCLA) to develop a biobank that can be used to characterize the durability and correlates of vaccine-induced and natural immunity to Ebola virus disease (EVD). The $7,332,682.00 contract has an ultimate completion date of March 22, 2025. UCLA will leverage its facilities, faculty expertise, and administrative capabilities to support this FDA initiative. The...
- This is a $1,603,602.00 firm fixed-price definitive contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to the University of California, Los Angeles (UCLA) for support of the RCADS data collection measure. The contract has an ultimate completion date of July 31, 2026. UCLA, a state-controlled institution of higher learning, frequently serves as a prime contractor for federal research and technical services. This contract is not set aside for any specific...
- This is a firm fixed-price purchase order valued at $25,000.00 awarded by the Food and Drug Administration (FDA) to the University of California, Los Angeles (UCLA), doing business as the Office of Research Administration. The contract is for the provision of Occupational Safety and Health (OSH) training materials and safety training support to the Safety Training Consortium. The award has no set-aside designation and will be performed by UCLA at its facilities in Los Angeles, California. As the...
- This is a $1,050,310 firm fixed-price definitive contract awarded by the Food and Drug Administration (FDA) to the Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The contract, which has no set-aside designation, is for a project titled "CDER NEURODEVELOPMENTAL AND MENTAL HEALTH OUTCOMES IN PRETERM INFANTS: EFFECTS OF EXP" with a period of performance ending on March 7, 2025. The contract was awarded under a Broad Agency...
- The Regents of the University of California, doing business as the University of California San Francisco Controller's Office, was awarded a $564,554 firm fixed price purchase order by the United States Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Executive Programs Division of Learning and Organizational Development. Under this contract, the University of California San Francisco will provide Drug Development and...
- This is a $699,087 firm-fixed price definitive contract awarded by the Food and Drug Administration (FDA) to Duke University, a prestigious private research institution located in Durham, North Carolina. The contract is for basic and applied research and development to support regulatory science and innovation, in alignment with the FDA's mission to protect and promote public health. This award is part of the FDA's agency-wide Broad Agency Announcement (BAA) for research and development. The...
- This definitive firm fixed-price contract, valued at $249,582.00, was awarded by the Food and Drug Administration (FDA) to the University of Southern California (USC) to support literature research necessary to identify potential areas to study. The contract has a completion date of December 31, 2024 and was issued without a set-aside designation. USC, a prestigious private research university, regularly performs work for the federal government through contract and grant awards managed by its...
- This is a $566,404.67 firm fixed-price contract awarded by the Food and Drug Administration (FDA) to the University of California, San Francisco (UCSF) to conduct a multidisciplinary study on stimulant use disorders. The contract, which does not have a set-aside designation, aims to gain a greater understanding of trajectories towards stimulant use disorders through qualitative research at three sites: San Francisco, West Virginia, and Nebraska. UCSF is collaborating with the University of...
- This is a $2,275,305.00 definitive cost-no-fee contract awarded by the U.S. Food and Drug Administration (FDA) to Children's Hospital Los Angeles (CHLA) with a performance period through June 16, 2024. The contract is for the development of a model that integrates inflammation and tissue injury to predict and mitigate the post-acute sequelae of COVID-19. As prime contractor, CHLA has subcontracted portions of the work to the University of Southern California and the University of California, Los...